Your post makes sense and you’re probably right on the definition of cEVR in ZGEN’s PR. As noted earlier in this thread, it would save investors a lot of hassle if the HCV companies and “thought leaders” could agree on industry-standard terminology for the non-SVR efficacy metrics and the various patient subgroups in the second-line setting. Is this too much to expect?
Market Data 
Markets 
AI
